The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial

Trial Profile

The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Bivalirudin (Primary)
  • Indications Coronary disorders
  • Focus Therapeutic Use
  • Acronyms REPLACE-2
  • Most Recent Events

    • 20 Apr 2016 Results of a pooled analysis from REPLACE-2, ACUITY and HORIZONS-AMI Trials (n=3641) published in the American Journal of Cardiology
    • 30 Dec 2015 New trial record
    • 01 Dec 2015 Results(n=14,784) of pooled analysis of this and other two trials (see profile 4808 and 21574) published in the American Journal of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top